Brief: Wilex unit Heidelberg Pharma signs license agreement with Max Delbrück Center

Heidelberg Pharma AG

25/01/2017 10:02

Jan 25 (Reuters) - Wilex AG  WL6G.DE : 
    * Subsidiary Heidelberg Pharma exercises option on BCMA 
antibodies of the Max Delbrück Center and signs license 
agreement 
    * Financial details are confidential but will not have a 
material impact on Wilex' cash reach. 
 
Source text for Eikon:  ID:nEQ5gwM6g  
Further company coverage:  WL6G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 722 0920;))